AACR 2023 | Do ADCs have a future in treating breast cancer?
Filipa Lynce, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the role of antibody-drug conjugates (ADCs) in treating breast cancer. They have been successful in treating many subtypes of breast cancer including HER2-positive, HER2-low, and triple-negative breast cancer (TNBC). Further research is required to assess their utility in combination with other agents such as chemotherapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, I think that’s antibody drug conjugates or the smart bombs as some people call it, given that you can deliver higher doses of the payloads in a more targeted way. We have seen the antibody drug conjugates being approved in HER2 positive breast cancer followed by triple negative breast cancer: now HER2 low. And we are seeing a efficacy of these agents using different antibodies, using different payloads in all of our in all the subtypes of breast cancer...
So, I think that’s antibody drug conjugates or the smart bombs as some people call it, given that you can deliver higher doses of the payloads in a more targeted way. We have seen the antibody drug conjugates being approved in HER2 positive breast cancer followed by triple negative breast cancer: now HER2 low. And we are seeing a efficacy of these agents using different antibodies, using different payloads in all of our in all the subtypes of breast cancer. So, I would say I think that they are very promising agents that are here to stay and will be interesting to learn how we sequence all these novel agents not only among themselves with other ADCs but as well with the agents and older chemotherapies that have been already approved. So, which one do you use first?
Read more...
